Anti-PSCA monoclonal antibody - Agensys

Drug Profile

Anti-PSCA monoclonal antibody - Agensys

Alternative Names: AGS-1C4D4; AGS-PSCA; MK-4721

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Agensys
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pancreatic cancer; Prostate cancer

Most Recent Events

  • 02 Nov 2012 Discontinued - Phase-I for Prostate cancer in USA (IV)
  • 02 Nov 2012 Discontinued - Phase-II for Pancreatic cancer in Canada (IV)
  • 02 Nov 2012 Discontinued - Phase-II for Pancreatic cancer in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top